Vaxcyte Stock Performance
| PCVX Stock | USD 61.74 1.74 2.90% |
On a scale of 0 to 100, Vaxcyte holds a performance score of 14. The entity has a beta of 1.06, which indicates a somewhat significant risk relative to the market. Vaxcyte returns are very sensitive to returns on the market. As the market goes up or down, Vaxcyte is expected to follow. Please check Vaxcyte's treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to make a quick decision on whether Vaxcyte's existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxcyte are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Vaxcyte showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.9 | Five Day Return 7.96 | Year To Date Return 32.89 | Ten Year Return 136.1 | All Time Return 136.1 |
1 | Disposition of 74000 shares by Wassil Jim of Vaxcyte subject to Rule 16b-3 | 12/03/2025 |
2 | Vaxcyte Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade | 12/12/2025 |
3 | Disposition of 1000 shares by Elvia Cowan of Vaxcyte subject to Rule 16b-3 | 12/23/2025 |
4 | Disposition of 9743 shares by Dhaliwal Harpreet S. of Vaxcyte at 46.689 subject to Rule 16b-3 | 12/31/2025 |
5 | Vaxcyte Gains Positive Outlook with Price Target Boost - GuruFocus | 01/07/2026 |
6 | Vaxcyte launches proposed 500M public offering of stock, warrants - MSN | 01/29/2026 |
7 | Vaxcyte Announces Closing of 632.5 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares | 02/02/2026 |
8 | Vaxcyte to Present at the Guggenheim Emerging Outlook Biotech Summit | 02/05/2026 |
9 | Vaxcyte doses first participants in OPUS-3 trial - TipRanks | 02/12/2026 |
10 | Acquisition by Guggenhime Andrew of 4777 shares of Vaxcyte at 20.93 subject to Rule 16b-3 | 02/13/2026 |
11 | Aberdeen Group plc Boosts Holdings in Vaxcyte, Inc. PCVX | 02/18/2026 |
12 | A Look At Vaxcyte Valuation After OPUS-3 Phase 3 Dosing Milestone | 02/19/2026 |
13 | Earnings Outlook For Vaxcyte | 02/23/2026 |
| Begin Period Cash Flow | 389.2 M | |
| Total Cashflows From Investing Activities | 437.4 M |
Vaxcyte Relative Risk vs. Return Landscape
If you would invest 4,552 in Vaxcyte on November 30, 2025 and sell it today you would earn a total of 1,622 from holding Vaxcyte or generate 35.63% return on investment over 90 days. Vaxcyte is currently generating 0.5424% in daily expected returns and assumes 2.9252% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Vaxcyte, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaxcyte Target Price Odds to finish over Current Price
The tendency of Vaxcyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 61.74 | 90 days | 61.74 | about 1.49 |
Based on a normal probability distribution, the odds of Vaxcyte to move above the current price in 90 days from now is about 1.49 (This Vaxcyte probability density function shows the probability of Vaxcyte Stock to fall within a particular range of prices over 90 days) .
Vaxcyte Price Density |
| Price |
Predictive Modules for Vaxcyte
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vaxcyte. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vaxcyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vaxcyte Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vaxcyte is not an exception. The market had few large corrections towards the Vaxcyte's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vaxcyte, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vaxcyte within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.34 | |
β | Beta against Dow Jones | 1.06 | |
σ | Overall volatility | 5.30 | |
Ir | Information ratio | 0.11 |
Vaxcyte Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vaxcyte for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vaxcyte can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Net Loss for the year was (766.63 M) with loss before overhead, payroll, taxes, and interest of (75 M). | |
| Vaxcyte currently holds about 354.5 M in cash with (655.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98. | |
| Vaxcyte has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: Earnings Outlook For Vaxcyte |
Vaxcyte Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vaxcyte Stock often depends not only on the future outlook of the current and potential Vaxcyte's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vaxcyte's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 136.1 M | |
| Cash And Short Term Investments | 1.6 B |
Vaxcyte Fundamentals Growth
Vaxcyte Stock prices reflect investors' perceptions of the future prospects and financial health of Vaxcyte, and Vaxcyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaxcyte Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 6.99 B | ||||
| Shares Outstanding | 143.56 M | ||||
| Price To Book | 2.98 X | ||||
| Gross Profit | (75 M) | ||||
| EBITDA | (741.77 M) | ||||
| Net Income | (766.63 M) | ||||
| Cash And Equivalents | 354.5 M | ||||
| Cash Per Share | 5.98 X | ||||
| Total Debt | 117.48 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 11.94 X | ||||
| Book Value Per Share | 20.49 X | ||||
| Cash Flow From Operations | (655.58 M) | ||||
| Earnings Per Share | (4.85) X | ||||
| Market Capitalization | 8.71 B | ||||
| Total Asset | 3 B | ||||
| Retained Earnings | (2.15 B) | ||||
| Working Capital | 1.65 B | ||||
About Vaxcyte Performance
Evaluating Vaxcyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vaxcyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vaxcyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.26) | |
| Return On Capital Employed | (0.33) | (0.34) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | (0.29) | (0.30) |
Things to note about Vaxcyte performance evaluation
Checking the ongoing alerts about Vaxcyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaxcyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (766.63 M) with loss before overhead, payroll, taxes, and interest of (75 M). | |
| Vaxcyte currently holds about 354.5 M in cash with (655.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98. | |
| Vaxcyte has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: Earnings Outlook For Vaxcyte |
- Analyzing Vaxcyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaxcyte's stock is overvalued or undervalued compared to its peers.
- Examining Vaxcyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaxcyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaxcyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaxcyte's stock. These opinions can provide insight into Vaxcyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.